| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/01/2011 | CN102078554A Chinese traditional medicine for immune regulation and preparation method thereof |
| 06/01/2011 | CN102078394A Aconite extract-containing medicinal composition, preparation method and application thereof |
| 06/01/2011 | CN102078372A Chinese herbal medicine composition for enhancing disease resistance of broiler chickens |
| 06/01/2011 | CN102078367A Use of aidi preparation in preparation of medicaments for treating multiple organ dysfunction syndrome in elderly |
| 06/01/2011 | CN102078366A Hemsley rockvine root lozenge for diminishing inflammation and resisting viruses and preparation method thereof |
| 06/01/2011 | CN102078354A Medicine composition capable of improving immunity and preparation method thereof |
| 06/01/2011 | CN102078345A Preparation method of actinidia arguta flavonoids |
| 06/01/2011 | CN102078339A Method for enriching and purifying common phellinus fungus general flavone in common phellinus fungus |
| 06/01/2011 | CN102078329A Method for preparing concentration-controllable broiler spleen transfer factor oral solution |
| 06/01/2011 | CN102078326A Topically applied composition containing povidone iodine and mometasone furoate |
| 06/01/2011 | CN102078286A In-situ gel containing ciclesonide for noses |
| 06/01/2011 | CN102078285A Nasal in-situ gel containing corticosteroids and H1 receptor antagonists |
| 06/01/2011 | CN102077928A Tilapia immune potentiator and preparation method thereof |
| 06/01/2011 | CN101669905B Thymosin alpha1 injection-type subcutaneous implant |
| 06/01/2011 | CN101537050B Health product capable of enhancing bone density and immune function, and preparation method and applications thereof |
| 05/31/2011 | US7951820 Triazole compounds useful as protein kinase inhibitors |
| 05/31/2011 | US7951772 Tumor-activated prodrug compounds and treatment |
| 05/31/2011 | US7951585 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof |
| 05/31/2011 | US7951386 Recombinant cytochrome oxidase and/or morula membrane protein for use in developing therapeutics which prevent infection associated with mite parasitfes |
| 05/31/2011 | US7951371 Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling |
| 05/31/2011 | CA2483241C Novel diazabicyclononene derivatives |
| 05/31/2011 | CA2475764C New inhibitors of histone deacetylase |
| 05/31/2011 | CA2466135C Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease |
| 05/31/2011 | CA2465750C 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]-indole-1-carboxamide derivatives, their preparation and therapeutic use |
| 05/31/2011 | CA2398539C Myeloid colony stimulating factor and uses thereof |
| 05/31/2011 | CA2339324C Protein delivery system using human papillomavirus virus-like particles |
| 05/31/2011 | CA2321903C Live recombinant vaccines comprising an adjuvant compound and a viral vector comprising a gene of an animal herpes or influenza virus |
| 05/26/2011 | WO2011063277A1 Anti-orai1 antigen binding proteins and uses thereof |
| 05/26/2011 | WO2011063102A1 Apremilast for the treatment of sarcoidosis |
| 05/26/2011 | WO2011062332A1 A method for extracting ginsenosides-abundant extract from ginseng by using weak alkali water |
| 05/26/2011 | WO2011062253A1 Novel fused pyrimidine derivative |
| 05/26/2011 | WO2011061743A1 Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders |
| 05/26/2011 | WO2011061119A1 Humanized antibodies against human il-22ra |
| 05/26/2011 | WO2010120541A3 Compositions and methods for modulating the activity of complement regulatory proteins on target cells |
| 05/26/2011 | US20110126301 Dendritic Cell Marker and Uses Thereof |
| 05/26/2011 | US20110124705 Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| 05/26/2011 | US20110124696 Sulfone Compounds Which Modulate The CB2 Receptor |
| 05/26/2011 | US20110124693 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory diseases |
| 05/26/2011 | US20110124683 Use of CRTH2 Antagonist Compounds |
| 05/26/2011 | US20110124669 Modulators of Cellular Adhesion |
| 05/26/2011 | US20110124668 Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| 05/26/2011 | US20110124645 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| 05/26/2011 | US20110124643 Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof |
| 05/26/2011 | US20110124640 Fused heterocyclic compounds useful as kinase modulators |
| 05/26/2011 | US20110124636 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
| 05/26/2011 | US20110124625 Modulators of Cellular Adhesion |
| 05/26/2011 | US20110124624 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory diseases |
| 05/26/2011 | US20110124614 Methods And Compositions For The Treatment of Autoimmune Disorders |
| 05/26/2011 | US20110124605 Use of an S1P Receptor Agonist |
| 05/26/2011 | US20110124599 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses |
| 05/26/2011 | US20110124560 Foxp3 oligomerization and intermolecular interactions |
| 05/26/2011 | US20110124552 GMCSF and Truncated CCL2 Conjugates and Methods and Uses Thereof |
| 05/26/2011 | US20110123648 Use of coconut water extract or coconut shell extract for treating immunological diseases and/or disorders |
| 05/26/2011 | US20110123637 Protamine/rna nanoparticles for immunostimulation |
| 05/26/2011 | US20110123632 Nanoscale Adjuvants and Related Pharmaceutical Compositions and Methods |
| 05/26/2011 | US20110123625 Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes |
| 05/26/2011 | US20110123620 Silicon dioxide nanoparticles and the use thereof for vaccination |
| 05/26/2011 | US20110123601 Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery |
| 05/26/2011 | US20110123596 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 05/26/2011 | US20110123570 Actinobacillus suis antigens |
| 05/26/2011 | US20110123568 Novel use |
| 05/26/2011 | US20110123566 Endogenous adjuvant molecules and uses thereof |
| 05/26/2011 | US20110123565 Structural Proteins of Fish Pancreatic Disease Virus and Uses Thereof |
| 05/26/2011 | US20110123561 Methods and compositions for induction or promotion of immune tolerance |
| 05/26/2011 | US20110123558 Peptide with Reduced Dimer Formation |
| 05/26/2011 | US20110123556 Immunogen prioritization for vaccine design |
| 05/26/2011 | US20110123552 Agonistic binding molecules to the human OX40 receptor |
| 05/26/2011 | US20110123551 Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use |
| 05/26/2011 | US20110123544 Human antibodies that bind human il-12 and methods for producing |
| 05/26/2011 | US20110123543 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 05/26/2011 | US20110123540 Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
| 05/26/2011 | US20110123537 Binding epitopes for g250 antibody |
| 05/26/2011 | US20110123531 Combination therapy |
| 05/26/2011 | US20110123528 Humanized anti-factor d antibodies and uses thereof |
| 05/26/2011 | US20110123502 Method for obtaining treg-cells |
| 05/26/2011 | US20110123492 Immunity-inducing agent |
| 05/26/2011 | US20110123491 Methods and compositions for immunization against chlamydial infection and disease |
| 05/26/2011 | US20110123490 Heterocyclic antiviral compounds |
| 05/26/2011 | US20110123484 Methods and compositions for treating fus1 related disorders |
| 05/26/2011 | US20110123452 Metal oligomers and polymers and their use in biology and medicine |
| 05/26/2011 | US20110123436 Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA |
| 05/26/2011 | US20110123435 Compounds for inhibiting ksp kinesin activity |
| 05/26/2011 | DE102009054302A1 Chinazolinderivate Quinazoline derivatives |
| 05/26/2011 | CA2781532A1 Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1 |
| 05/26/2011 | CA2781397A1 Compositions, methods and uses for poxvirus elements in vaccine constructs |
| 05/26/2011 | CA2780487A1 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| 05/26/2011 | CA2778864A1 Humanized antibodies against human il-22ra |
| 05/26/2011 | CA2777719A1 Apremilast for the treatment of sarcoidosis |
| 05/25/2011 | EP2325317A1 Receptor nucleic acids and polypeptides |
| 05/25/2011 | EP2325205A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325184A1 Azaindoles useful as inhibitors of protein kinases |
| 05/25/2011 | EP2325175A1 2,4-diaminopyrimidine compound |
| 05/25/2011 | EP2325174A1 Sigma receptor inhibitors |
| 05/25/2011 | EP2325169A2 Lisofylline analogues and their pharmeacuetical uses |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324849A2 Selective immune down regulation (SIDR) mediated transplantation processes |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324842A1 Immunity-inducing agent |
| 05/25/2011 | EP2324826A1 Hydrophilic amino acid-containing preparation having improved taste |